Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure

This study aimed to determine the maximum tolerated dose (MTD), dose-limiting toxicity, and efficacy of second-line chemotherapy with FOLFIRINOX after gemcitabine (GEM)-based chemotherapy failure in metastatic pancreatic cancer (MPC). We studied 18 histopathologically proven MPC patients. The schedu...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Medicine (Baltimore) 2017-05, Vol.96 (19), p.e6769-e6769
Hauptverfasser:	Kobayashi, Noritoshi, Shimamura, Takeshi, Tokuhisa, Motohiko, Goto, Ayumu, Endo, Itaru, Ichikawa, Yasushi
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Camptothecin - administration & dosage Camptothecin - adverse effects Camptothecin - analogs & derivatives Clinical Trial/Experimental Study Deoxycytidine - analogs & derivatives Deoxycytidine - therapeutic use Disease-Free Survival Dose-Response Relationship, Drug Drug Resistance, Neoplasm Female Fluorouracil - administration & dosage Fluorouracil - adverse effects Follow-Up Studies Gemcitabine Humans Irinotecan Kaplan-Meier Estimate Leucovorin - administration & dosage Leucovorin - adverse effects Male Maximum Tolerated Dose Middle Aged Organoplatinum Compounds - administration & dosage Organoplatinum Compounds - adverse effects Oxaliplatin Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - pathology Retreatment Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!